Compounds > camptothecin
Page last updated: 2024-08-22

camptothecin and st 1481

camptothecin has been researched along with st 1481 in 40 studies

Research

Studies (40)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's28 (70.00)29.6817
2010's12 (30.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Beretta, G; Biasotti, B; Carenini, N; Carminati, P; Dallavalle, S; De Cesare, M; Ferrari, A; Gallo, G; Martinelli, R; Marzi, M; Merlini, L; Penco, S; Perego, P; Pisano, C; Pratesi, G; Tinti, MO; Zunino, F1
Battistuzzi, G; Beretta, GL; Cabri, W; De Cesare, M; Giannini, G; Marastoni, E; Marzi, M; Pisano, C; Vesci, L; Zunino, F1
Beggiolin, G; Carenini, N; Carminati, P; De Cesare, M; De Isabella, P; Palumbo, M; Perego, P; Pezzoni, G; Pisano, C; Pratesi, G; Scheffer, GL; Tartaglia, L; Zunino, F1
Bucci, F; Capocasa, F; Carenini, N; Carminati, P; De Cesare, M; Merlini, L; Pace, S; Penco, S; Perego, P; Pisano, C; Pratesi, G; Tinelli, S; Vesci, L; Zunino, F1
Carenini, N; Carminati, P; Cucco, C; De Cesare, M; Merlini, L; Penco, S; Perego, P; Pisano, C; Pratesi, G; Righetti, SC; Vesci, L; Zunino, F1
Bucci, F; Carenini, N; Carminati, P; De Cesare, M; Gatti, L; Martinelli, R; Perego, P; Pisano, C; Pratesi, G; Supino, R; Zanier, R; Zuco, V; Zunino, F1
De Cesare, M; Giordano, V; Laccabue, D; Lanzi, C; Marcellini, M; Petrangolini, G; Pisano, C; Pratesi, G; Supino, R; Zunino, F1
Bottiroli, G; Croce, AC; Favini, E; Supino, R; Zuco, V; Zunino, F1
Beretta, GL; Pratesi, G; Zunino, F1
Barbarino, M; Bucci, F; Bufali, S; Carminati, P; Luisi, PL; Pisano, C; Santaniello, M; Stano, P1
Bergottini, R; De Cesare, M; Pratesi, G; Veneroni, S; Zunino, F1
Salmons, B1
Beretta, GL; Brigliadori, G; Corna, E; De Cesare, M; Fabbri, F; Ricotti, L; Rosetti, M; Supino, R; Tesei, A; Ulivi, P; Zoli, W; Zunino, F1
Balsari, A; Carenini, N; De Cesare, M; Del Bufalo, D; Perego, P; Pratesi, G; Righetti, SC; Rivoltini, L; Zunino, F; Zupi, G1
Nitiss, JL; Nitiss, KC1
Barone, G; Carminati, P; D'Incalci, M; Di Francesco, AM; Frapolli, R; Meco, D; Pisano, C; Riccardi, A; Riccardi, AS; Riccardi, R; Rutella, S; Zucchetti, M1
Carenini, N; Ciusani, E; Corna, E; Gatti, L; Perego, P; Zunino, F1
Baselga, J; Capri, G; Carminati, P; Cerny, T; Cresta, S; D'Incalci, M; Gatti, B; Gianni, L; Hess, D; Malossi, A; Marsoni, S; Rota Caremoli, E; Sessa, C; Trigo, J; Zaniboni, A; Zanna, C; Zucchetti, M1
Gounder, MK; Kulkarni, D; Nazar, AS; Pungaliya, P; Rubin, EH; Saleem, A; Versace, R1
Teicher, BA1
Beijnen, JH; Marchetti, S; Mazzanti, R; Oostendorp, RL; Pluim, D; Schellens, JH; Schinkel, AH; van Eijndhoven, M; van Tellingen, O; Versace, R1
Balsari, A; Carenini, N; De Cesare, M; Perego, P; Petrangolini, G; Pratesi, G; Tortoreto, M; Zunino, F1
Bernacki, RJ1
David, K; Drappatz, J; Gerard, M; Kesari, S; McNamara, MB; Muzikansky, A; Norden, AD; Phan, P; Ross, A; Wen, PY1
Amato, A; Clark, JW; He, X; Lynch, TJ; Pace, S; Ready, N; Ryan, DP; Safran, H; Salem, N; Supko, JG; Zhu, AX; Zvereva, N1
Beijnen, JH; Kenworthy, KE; Oostendorp, RL; Schellens, JH; Schinkel, AH; van de Steeg, E; van der Kruijssen, CM1
Alloatti, D; Arimondo, PB; Bailly, C; Boutorine, A; Dallavalle, S; Giannini, G; Halby, L; Lansiaux, A; Mahieu, C; Merlini, L; Oussedik, K; Pisano, C; Vekhoff, P1
Capocasa, F; Frapolli, R; Longo, A; Pace, S; Tallarico, C; Zucchetti, M1
Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W1
Barbieri, P; Brienza, S; Carminati, P; Colombo, N; du Bois, A; Frigerio, L; Guastalla, JP; Katsaròs, D; Lhommé, C; Lissoni, AA; Parma, G; Pecorelli, S; Poveda, A; Ray-Coquard, I; Tisi, G; Tredan, O; Vermorken, JB1
Bello, E; Carminati, P; Compagnoni, A; D'Incalci, M; Frapolli, R; Locatelli, A; Marsoni, S; Pisano, C; Rulli, E; Sessa, C; Viganò, L; Zucchetti, M1
Cusano, G; D'Incalci, M; Di Francesco, AM; Forestieri, D; Meco, D; Patriarca, V; Pisano, C; Riccardi, R; Servidei, T; Zucchetti, M1
Beretta, G; Biroccio, A; D'Angelo, C; Franceschin, M; Gilson, E; Leonetti, C; Orlandi, A; Passeri, D; Pisano, C; Porru, M; Rizzo, A; Salvati, E; Stevens, MF; Zunino, F; Zupi, G1
Abrey, LE; Drappatz, J; Fadul, CE; Hochberg, F; Hu, J; Salem, N; Supko, JG; Wen, PY1
Beijnen, JH; Iusuf, D; Lin, F; Marchetti, S; Mazzanti, R; Pluim, D; Schellens, JH; van Tellingen, O1
Alvarez-Velilla, R; Balaña-Fouce, R; Calvo-Álvarez, E; Desideri, A; Escudero-Martínez, JM; Ordóñez, C; Pérez-Pertejo, Y; Prada, CF; Prieto, C; Reguera, RM; Requena, JM1
Chen, D; Chen, Z; Gao, J; Hu, Y; Huang, W; Ji, J; Li, B; Li, Z; Lin, X; Liu, Z; Shen, L; Wang, J; Zou, J1
Chen, Z; Gao, J; Li, S; Li, Y; Lin, X; Lu, Z; Shen, L; Zhang, C; Zou, J1
Cincinelli, R; Dallavalle, S; De Santis, R; Giannini, G; Minenkova, O; Musso, L; Santapaola, D; Vesci, L1
DE Cesare, M1

Reviews

3 review(s) available for camptothecin and st 1481

ArticleYear
Gimatecan, a novel camptothecin with a promising preclinical profile.
    Anti-cancer drugs, 2004, Volume: 15, Issue:6

    Topics: Administration, Oral; Animals; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Multicenter Studies as Topic

2004
Gimatecan (sigma-tau industrie farmaceutiche riunite/novartis).
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:7

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Camptothecin; Chemistry, Pharmaceutical; Clinical Trials, Phase II as Topic; Humans; Molecular Structure; Neoplasms

2005
Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
    Biochemical pharmacology, 2008, Mar-15, Volume: 75, Issue:6

    Topics: Animals; Antineoplastic Agents; Biomarkers; Camptothecin; Carbazoles; Humans; Indenes; Indoles; Isoquinolines; Naphthyridines; Topoisomerase I Inhibitors

2008

Trials

5 trial(s) available for camptothecin and st 1481

ArticleYear
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:3

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Half-Life; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome

2007
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jan-01, Volume: 15, Issue:1

    Topics: Administration, Oral; Adult; Aged; Camptothecin; Drug Administration Schedule; Female; Humans; In Vitro Techniques; Maximum Tolerated Dose; Middle Aged; Neoplasms

2009
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Recurrence; Taxoids

2010
Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Blood Specimen Collection; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Half-Life; Humans; Mice; Mice, Nude; Middle Aged; Orosomucoid; Ovarian Neoplasms; Xenograft Model Antitumor Assays; Young Adult

2010
A phase II trial of oral gimatecan for recurrent glioblastoma.
    Journal of neuro-oncology, 2013, Volume: 111, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome

2013

Other Studies

32 other study(ies) available for camptothecin and st 1481

ArticleYear
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity.
    Journal of medicinal chemistry, 2001, Sep-27, Volume: 44, Issue:20

    Topics: Animals; Antineoplastic Agents; Camptothecin; DNA; DNA Topoisomerases, Type I; Drug Screening Assays, Antitumor; Humans; Imines; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Nude; Quantitative Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured

2001
E-ring-modified 7-oxyiminomethyl camptothecins: Synthesis and preliminary in vitro and in vivo biological evaluation.
    Bioorganic & medicinal chemistry letters, 2008, May-01, Volume: 18, Issue:9

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Stereoisomerism; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2008
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Cancer research, 2001, Aug-15, Volume: 61, Issue:16

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; DNA Damage; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; HT29 Cells; Humans; Mice; Mice, Nude; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Topotecan; Xenograft Model Antitumor Assays

2001
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.
    Cancer research, 2001, Oct-01, Volume: 61, Issue:19

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Liver Neoplasms, Experimental; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2001
Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:12

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Cell Division; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2002
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
    Biochemical pharmacology, 2003, Apr-15, Volume: 65, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; DNA Damage; DNA, Neoplasm; Humans; Male; Prostatic Neoplasms; Topotecan; Tumor Cells, Cultured

2003
Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts.
    Molecular cancer research : MCR, 2003, Volume: 1, Issue:12

    Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Transplantation, Heterologous; Tumor Cells, Cultured

2003
Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
    Biochemical pharmacology, 2004, Mar-15, Volume: 67, Issue:6

    Topics: Antineoplastic Agents; Camptothecin; DNA Damage; HT29 Cells; Humans; Spectrometry, Fluorescence; Subcellular Fractions; Topotecan; Tumor Cells, Cultured

2004
Novel camptothecin analogue (gimatecan)-containing liposomes prepared by the ethanol injection method.
    Journal of liposome research, 2004, Volume: 14, Issue:1-2

    Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Stability; Ethanol; Humans; Liposomes; Mice; Molecular Structure; Neoplasms, Experimental; Particle Size; Stereoisomerism; Water

2004
Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-01, Volume: 10, Issue:21

    Topics: Animals; Brain; Camptothecin; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Nervous System Neoplasms; Ovarian Neoplasms; Time Factors; Xenograft Model Antitumor Assays

2004
Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA.
    IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:3

    Topics: Antineoplastic Agents; Benzamides; Camptothecin; Cell- and Tissue-Based Therapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Entrepreneurship; Genetic Therapy; Humans; Imatinib Mesylate; Imidazoles; Molecular Structure; Phthalazines; Piperazines; Pyridines; Pyrimidines; Zoledronic Acid

2005
Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.
    Neoplasia (New York, N.Y.), 2005, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Camptothecin; Disease Models, Animal; DNA Topoisomerases, Type I; Down-Regulation; Female; Humans; Mice; Mice, Nude; Protease Inhibitors; Pyrazines; RNA, Messenger; S Phase; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Urinary Bladder Neoplasms

2005
Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts.
    European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:8

    Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Transplantation; Proto-Oncogene Proteins c-bcl-2; Thionucleotides; Transplantation, Heterologous

2005
The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan.
    Biochemical pharmacology, 2005, Oct-15, Volume: 70, Issue:8

    Topics: Antineoplastic Agents; Camptothecin; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Comet Assay; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Irinotecan; Neuroblastoma; Topotecan

2005
Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells.
    Biochemical pharmacology, 2006, Mar-14, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Camptothecin; Caspase 8; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Gene Silencing; Genetic Vectors; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Transfection; Tumor Necrosis Factor-alpha; Up-Regulation

2006
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
    Investigational new drugs, 2008, Volume: 26, Issue:3

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dogs; Drug Resistance, Neoplasm; Gene Expression; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Mutation; Topotecan; Transfection

2008
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:12 Pt 1

    Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; Dogs; Drug Interactions; Humans; Membrane Transport Proteins; Methotrexate; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins

2007
Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft.
    Cancer biology & therapy, 2008, Volume: 7, Issue:4

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Xenograft Model Antitumor Assays

2008
Metronomic chemotherapy and tumor immunomodulation.
    Cancer biology & therapy, 2008, Volume: 7, Issue:4

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Mice; Mice, Nude; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays

2008
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma.
    Journal of neuro-oncology, 2009, Volume: 92, Issue:2

    Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Carbazoles; Clinical Trials as Topic; Disease-Free Survival; Female; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis

2009
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
    Drug metabolism and disposition: the biological fate of chemicals, 2009, Volume: 37, Issue:4

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line; Dogs; Humans; Liver-Specific Organic Anion Transporter 1; Neoplasm Proteins; Organic Anion Transporters

2009
Optimized synthesis and enhanced efficacy of novel triplex-forming camptothecin derivatives based on gimatecan.
    Bioconjugate chemistry, 2009, Volume: 20, Issue:4

    Topics: Camptothecin; Cells; Deoxyribonucleases; DNA; HeLa Cells; Humans; Oximes

2009
Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by high-performance liquid chromatography with fluorimetric detection.
    Journal of pharmaceutical and biomedical analysis, 2009, Oct-15, Volume: 50, Issue:3

    Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Reproducibility of Results

2009
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.
    The Prostate, 2010, Feb-01, Volume: 70, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids

2010
Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4

    Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cell Line, Tumor; Cell Proliferation; Child; Chromatography, High Pressure Liquid; Half-Life; Humans; Irinotecan; Male; Mice; Mice, Nude; Neuroblastoma; Rhabdomyosarcoma; Tetrazolium Salts; Thiazoles; Xenograft Model Antitumor Assays

2010
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8

    Topics: Acridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Survival; Cells, Cultured; Colonic Neoplasms; DNA Damage; Drug Synergism; G-Quadruplexes; HCT116 Cells; HT29 Cells; Humans; Irinotecan; Male; Mice; Mice, Nude; Telomere; Topoisomerase I Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays

2011
Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Apr-15, Volume: 19, Issue:8

    Topics: Acridines; Administration, Intravenous; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Camptothecin; Chromatography, High Pressure Liquid; Irinotecan; Mice; Mice, Knockout; Multidrug Resistance-Associated Proteins; Tetrahydroisoquinolines; Topotecan

2013
Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect.
    Biochemical pharmacology, 2013, May-15, Volume: 85, Issue:10

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cells, Cultured; DNA Topoisomerases, Type I; Genes, Reporter; Inhibitory Concentration 50; Irinotecan; Kinetics; Leishmania infantum; Life Cycle Stages; Luminescent Proteins; Mice; Prodrugs; Protozoan Proteins; Red Fluorescent Protein; Spleen; Topoisomerase I Inhibitors; Trypanocidal Agents

2013
Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
    Journal of translational medicine, 2017, Dec-13, Volume: 15, Issue:1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Female; Humans; Ki-67 Antigen; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-akt; Stomach Neoplasms; Time Factors; Xenograft Model Antitumor Assays

2017
A novel oral camptothecin analog, gimatecan, exhibits superior antitumor efficacy than irinotecan toward esophageal squamous cell carcinoma in vitro and in vivo.
    Cell death & disease, 2018, 05-31, Volume: 9, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases, Type I; Esophageal Squamous Cell Carcinoma; Humans; Irinotecan

2018
Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative.
    Bioorganic & medicinal chemistry letters, 2018, 11-01, Volume: 28, Issue:20

    Topics: Animals; Antineoplastic Agents; Avidin; Biotin; Camptothecin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Female; Humans; Mice; Ovarian Neoplasms; Protein Binding

2018
High Efficacy of Intravenous Gimatecan on Human Tumor Xenografts.
    Anticancer research, 2018, Volume: 38, Issue:10

    Topics: Administration, Oral; Animals; Apoptosis; Astrocytoma; Bone Neoplasms; Camptothecin; Cell Proliferation; Colonic Neoplasms; Female; Humans; Mice; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2018